what we do
Commercializing biosimilars based on our long experience, novel technology, and a proven creative regulatory approach.
To be one of the largest biosimilars products company in the world, focussing on development and regulatory approval within the shortest time possible.
What We've Achieved
- Identified 25 biosimilar candidates with least resistance, both legal and financial, to enter the market.
- Licensed in or developed several products with current market of over $50 Billion.
- Created development master plans (DMP) for each product including detailed cost and timeline in consultation with FDA.
- Applied proprietary technology to reduce the development cost by more than 60%.
- Secured FDA comments on two lead products--ready for IND filing.
- Identified potential commercial sponsors ranging from establish biotech companies to specialty product distributors.
- Reduced the traditional cost of development by 60-80%.